A “living drug” that could change the way we ...

Six months into a catastrophic war in Iran — and with no end in sight for the war in Ukraine — the world is embroiled in conflicts with no apparent exit plan. In this interview, political scientist and Eurasia Group founder Ian Bremmer breaks down what these wars are costing peop ...  Show more

Is authoritarianism winning, or is democracy just failing to deliver? Communications strategist Sally Kohn lays out how democracy has evolved before and why it must evolve again, into what she calls "Democracy 3.0" — a version that finally shares power and opportunity equally. "W ...  Show more

Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.

Together, Carl and Jorge talked about Carl's pioneering work in CAR T therapy — including the terrifying moment where he thought he h ...

In this episode of “Intention to Treat,” host Rachel Gotbaum explores the story of a teenager who’s now in remission from previously relapsed lymphoblastic leukemia and talks with the investigator who developed the “off-the-shelf” CAR T cells that made her treatment possible. A f ...  Show more

CAR T cells are genetically engineered to express a receptor that recognizes and kills tumor cells. CAR T-cell products are now FDA approved for 6 hematologic malignancies. Author Jennifer N. Brudno, MD, National Cancer Institute, joins JAMA Deputy Editor Mary McGrae McDermott ...

In this episode, Dr. Hind Rafei dives into the cutting-edge world of CAR-NK cell therapy and its potential to revolutionize cancer treatment. Unlike their T-cell counterparts, CAR-NK cells promise enhanced safety and innate tumor-killing ability. But what if their power could ...